Richard Heyman was Appointed as Chief Executive Officer at ORIC-Pharmaceuticals

Date of management change: March 15, 2017 

What Happened?

2nd Floor, AB-based ORIC-Pharmaceuticals Appointed Richard Heyman as Chief Executive Officer

 

About the Company

ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.

 

About the Person

Richard Heyman is Chief Executive Officer at ORIC Pharmaceuticals. Previously, Richard held various senior HR leadership roles in the industry.

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Goeppner Lisa, Penry Kelly, Desai Abhijeet, Johnson Kathy, Marshalonis Monica, Nakano Christy, Ranese Thomas, Alexopoulos George, Wright Barry, Fisher Shane, Holt Laura

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.